- Company
- Awareness of multiple sclerosis should increase
- by Jun 3, 2021 06:12am
- Today (26th) is World MS Day. Although the treatment environment has improved significantly with the release of more new drugs for multiple sclerosis compared to the past, early diagnosis is not easy due to the low awareness of the disease. The same is true of overseas situations. In response, the International Association for Multiple Sclero
- Company
- Tecentriq attempts reimbursement after Keytruda fails
- by Eo, Yun-Ho Jun 2, 2021 06:11am
- ‘Tecentriq’ is attempting what ‘Keytruda’ had failed. Industry sources have said that Roche Korea had submitted an application for the reimbursement of its ‘Tecentriq (atezolizumab),’ as monotherapy in the first-line setting for non-small cell lung cancer (NSCLC) patients whose tumors have a programmed death ligand-1 (PD-L1) express
- Company
- Improved reg. allow price succession of transfer products
- by Chon, Seung-Hyun Jun 2, 2021 06:10am
- Drug price succession in transferred pharmaceutical products has been increasing. As the stepped pricing system is no longer applied to drugs that are relisted due to change of licensees, companies have been actively engaged in the transfer of their products. Some products have seen a twofold increase in their price compared to when the stepped
- Company
- The FDA's final decision on Rolontis remains
- by An, Kyung-Jin Jun 1, 2021 06:11am
- The FDA's due diligence on the domestic manufacturing facilities of Rolontis, a drug that Hanmi exported technology, has entered the final stage. The final process for obtaining final FDA approval has been completed as scheduled. Hanmi's partner Spectrum is rushing to prepare to enter the U.S. market worth about &8361;3 trillion in prepa
- Company
- 3-way race between ultra-expensive new orphan drugs to start
- by Jun 1, 2021 06:11am
- With Novartis’s gene therapy ‘Zolgensma’ approved, 3 new drugs have been introduced into the Korean spinal muscular atrophy (SMA) market, a market that previously had virtually no treatment available. The introduction of 3 new drugs in just 3 years marked the start of a full 3-way race between the new SMA treatments in Korea. In the U.S.
- Company
- Astellas notified distributors, Betmiga cannot be returned
- by Kim, Jin-Gu Jun 1, 2021 06:11am
- Confusion in pharmacies is expected to continue for a while over the lowering of the drug Betmiga (Mirabegron), an irritable bladder treatment. The pharmaceutical industry and the outpatient pharmacies predict that it will take at least a year for the drug price to be finalized. According to the pharmaceutical industry and pharmacies on th
- Company
- Beovu can be prescribed at general hospitals
- by Eo, Yun-Ho Jun 1, 2021 06:11am
- AMD treatment Beovu became available in general hospitals with insurance coverage. According to related industries, Novartis Korea's Beovu (Brolucizumab), which has been registered since April, passed drug committees of more than 30 medical institutions including Seoul National University Hospital and Sinchon Severance Hospital. Wet AMD
- Company
- Pacenra(Fasenra) can be prescribed at the general hospitals
- by Eo, Yun-Ho May 31, 2021 06:02am
- The severe asthma treatment "Pacenra" is available at general hospitals. According to related industries, Pacenra (or Fasenra, Benralizumab) of Astra Zeneca Korea has passed drug committee (DC) of medical institutions such as Samsung Medical Center, Seoul National University Hospital, Seoul National University Bundang Hospital , Ajou Univers
- Company
- Sales of Gaviscon and Strepsil continue to be sluggish
- by Kim, Jin-Gu May 31, 2021 06:01am
- Sales of Gaviscon and Strepsils have been sluggish for five years since Reckitt's boycott. It is shown that sales of two products decreased by 46% and 74% respectively in first quarter compared to before boycotting. Competitive items are found to benefit from the long-term sluggishness of the two products. According to IQVIA, a pharmaceuti
- Company
- Keytruda, passed the committee except for lung cancer
- by Eo, Yun-Ho May 31, 2021 06:01am
- According to the industry, yesterday (26th) the HIRA's Cancer Drugs Benefit Appraisal Committee recognized the appropriateness of immuno-cancer drug Keytruda (Pembrolizumab)'s ▲ bladder cancer 2nd or higher ▲ typical Hodgkin lymphoma solo therapy that recurred after 3rd treatment. In fact, NSCLC, Non-small Cell Lung Cancer's indication o
